Future Planet Capital

Idea

Introduction

Future Planet is the impact-led, global venture capital firm built to invest in high-growth companies from the world's top universities and research centres. As a first-mover in the impact investing space, we have now invested over $300M into 100+ startups and spinouts seeking to profitably solve the world's greatest challenges in Climate Change, Education, Health, Sustainable Growth & Security.

Founded by Douglas Hansen-Luke in 2015, with a track record investing across emerging asset classes for 30 years, FPC is one of the only venture groups in the world to benchmark impactful growth-stage companies emerging from the founders and science of the world’s top ten centres of innovation.

This origination network creates a rich pipeline of mission-aligned entrepreneurs with game-changing innovations. To date our impact investment thesis has seen us back Vaccitech, the company that’s now listed on NASDAQ having supplied 1bn COVID-19 doses worldwide; Guideline, among Americas fastest-growing pension providers; 23andMe, who recently completed a $3.5BN IPO; Tokamak, a world leader in the race to Fusion Energy and Aria, revolutionising AI drug discovery.

We were also the first institutional venture capital firm to open our business to the crowd. Now we return to Seedrs having grown 10x+ in the last year, and have reserved 10% of this round for the crowd, as part of our commitment to democratise venture.

Substantial accomplishments to date

Since our last Seedrs raise we have acquired 3 funds, grown well over 10x, creating a high-growth, high-margin business with the stability of a profitable company:

⦿ $6.5M TTM revenue, with $6M in long term contracted ARR*
⦿ 15x YoY growth (Q3 2020-2021), 3x 2021 Revenue Targets*
⦿ Already a profitable business*
3x Acquisitions completed bringing the team to 20 seasoned investment professionals and AUM to $300M, including:

⦿ UKI2S the UKRI backed deep tech Seed fund,
⦿ Midven the Midland’s oldest venture manager,
⦿ RT Capital, the Oxford & Cambridge VC fund, and
⦿ MAI, manager of the British Innovation Fund.

Our four core funds are now tracking top quartile, with notable IPOs and Acquisitions including:

⦿ 23andMe: $3.5Bn NASDAQ listing via Virgin SPAC
⦿ Vaccitech: £500M NASDAQ listing
⦿ Inivata: $390M acquisition by NeoGenomics
⦿ Quethera: ~100x exit with milestones to Astellas
⦿ Cobalt: 10x exit to Agilent

We have now established deeper partnerships with core strategic partners and investors, creating a formidable network:

⦿ Co-investment: Barclays for UHNWIs and institutional investors + plans for Seedrs to leverage the crowd.
⦿ Investors: additions include Sovereigns, a number of large Family Offices, the British Business Bank, European Investment Fund, Pensions and Corporates.
⦿ University: In addition to Oxford Science Enterprises, Harvard’s Xfund, MIT Media-Lab’s E14 Fund, Berkeley Skydeck, we now have the mandate to raise a fund with a top 3 US university.

Monetisation strategy

Three revenue streams combine to provide a strong diversified business:

1. Venture Funds: We manage over $300m in AUM across over 10 different venture funds, where we take on average a 2% fixed management fee, contracted for between 5-10+ years. Through acquisition and organic growth, our 5-year target is to grow this to $1-2Bn of Venture Assets. We also charge a 20% performance fee on these funds, of which 40% is retained by the company and the rest to our management team to ensure long-term alignment and commitment. Further, we are often investing a GP commitment, on which we expect a return.

2. Co-investment Platform: Large investors want access to our dealflow and the ability to invest alongside us. Our platform provides a steady flow of unique co-investment opportunities and pre-emption allocations, for which we charge management & performance fees. Our co-investors to date have included large royal family offices, corporates and institutions.

3. Introducer and Sub Advisory Business: We have signed partnerships to introduce deals to some of the largest private banks and corporations; we take introductory and management fees for specific mandates and deals that we have originated.

Use of proceeds

We plan to invest the use of proceeds into three core areas, to drive accretive AUM growth and cross-selling to hit our bottom line:

1. Consolidation of existing acquisitions increasing margins to create unencumbered free cashflows going forward, with the aim to drive profitability and ultimately dividends to shareholders. Please see the Key Information tab for further details.

2. Working capital to fund business development team to cross-sell and upsell our funds and portfolio companies, creating value and growth across our asset base.

3. Strategic Investment into 2-5 further JVs and partnerships to establish operations in North America and Asia.

In short, we plan for this capital to take us to the size and scale required to become a truly established global player in this space, in addition to providing a stable business for shareholders.

The next raise will likely be our last before eventually monetising through a direct listing, IPO, SPAC, reverse merger, minority stake exit, or outright acquisition by a larger asset manager